Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKH001 Safety and PK in Healthy Subjects (MAD)
NCT05991661Phase 2Completed
- Sponsor
- Beijing Kanova Biopharmaceutical
- Start
- May 2023
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing XKH001 Injection with Placebo (2 arms). Primary endpoints: Incidence of adverse events and serious adverse events at 24 weeks, Observation of injection site at 4 hours and 2 more. Started May 2023; status: completed.
02
Drugs
xkh001
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05991661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991661.